Murphy Oil Corporation <MUR.N>: Barclays cuts target price to $34 from $38
MUR•Related News
EyePoint says Phase 3 LUGANO trial of DURAVYU in wet AMD misses primary endpoint
EYPT•
United Therapeutics seeks FDA priority review for Tyvaso label expansion in IPF
UTHR•
Pacira BioSciences, Inc. <PCRX.O>: Truist Securities reinstates coverage with buy rating; price target $30
PCRX•
AngloGold Ashanti ups Thesis Gold & Silver stake to 9.7% in C$58.46 million share offering
AU•
Workday, Inc. <WDAY.O>: BTIG Cuts to Neutral From Buy
WDAY•